Journal of Leukocyte Biology eBioscience full spectrum cell analysis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

A more recent version of this article appeared on November 1, 2006

Published online before print August 17, 2006
This Article
Right arrow Full Text (Reprint (PDF))
Right arrow All Versions of this Article:
jlb.0306154v1
80/5/984    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hosmalin, A.
Right arrow Articles by Lebon, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hosmalin, A.
Right arrow Articles by Lebon, P.
© by The Society for Leukocyte Biology
Journal of Leukocyte Biology, doi:10.1189/jlb.0306154

Received for publication March 4, 2006.
Revised May 3, 2006.
Accepted for publication July 5, 2006.

Article

Type I interferon production in HIV-infected patients

Anne Hosmalin *@ and Pierre Lebon {dagger}

*Institut Cochin, Département d'Immunologie, Université Paris V René Descartes, Paris, France; and {dagger}Faculté de Médecine, Université René Descartes, Paris, France

@ To whom correspondence should be addressed. E-mail: anne.hosmalin{at}cochin.inserm.fr.


  Abstract

Type I IFNs display multiple biological effects. They have a strong antiviral action, not only directly but also indirectly through activation of the immune system. They may also have actions that are deleterious for the host. The cells that produce type I IFN are mostly plasmacytoid dendritic cells (pDC), but this depends on the viral stimulus. The migration and distribution of pDC into lymphoid organs, driven by chemokine interactions with their ligands, determines interaction with different cell types. In HIV infection, IFN production in vitro is impaired during primary infection and later in association with opportunistic infections. Circulating pDC numbers are decreased in parallel. These parameters may be used to help assess the prognosis of the disease and to monitor treatment.

Key Words: plasmacytoid dendritic cells • innate immunity • adaptive immunity • immune therapy • vaccination • primary infection • virus




This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
A. Iannello, O. Debbeche, S. Samarani, and A. Ahmad
Antiviral NK cell responses in HIV infection: II. viral strategies for evasion and lessons for immunotherapy and vaccination
J. Leukoc. Biol., July 1, 2008; 84(1): 27 - 49.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Fiorentini, E. Riboldi, F. Facchetti, M. Avolio, M. Fabbri, G. Tosti, P. D. Becker, C. A. Guzman, S. Sozzani, and A. Caruso
HIV-1 matrix protein p17 induces human plasmacytoid dendritic cells to acquire a migratory immature cell phenotype
PNAS, March 11, 2008; 105(10): 3867 - 3872.
[Abstract] [Full Text] [PDF]

Home page
 J. Leukoc. Biol.Home page
L. J. Montaner, S. M. Crowe, S. Aquaro, C.-F. Perno, M. Stevenson, and R. G. Collman
Advances in macrophage and dendritic cell biology in HIV-1 infection stress key understudied areas in infection, pathogenesis, and analysis of viral reservoirs
J. Leukoc. Biol., November 1, 2006; 80(5): 961 - 964.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2006 by the Society for Leukocyte Biology.